Contract research organisation Sinclair Research on Thursday announced an agreement to acquire the assets of the GLP safety pharmacology business unit of CorDynamics, a provider of cardiovascular toxicology and safety pharmacology contract research services.

The addition of CorDynamics' GLP safety pharmacology programme to Sinclair's growing nonclinical toxicology services is a good strategic fit and enables Sinclair to support critical IND-enabling programmes at a single research site, according to the company's vice president of commercial operations Andy Brown.

"Sinclair Research will be able to provide in vivo safety pharmacology studies, standalone or as part of an IND-enabling package, to help pharmaceutical developers assess the potential for adverse effects prior to first-in-human trials," he added.

"We're excited to offer non-GLP screening studies and GLP core battery studies in the future."

In addition to being able to support safety pharmacology core battery assessments of cardiovascular, respiratory and central nervous systems, Sinclair's strategic partnership with CorDynamics brings many years of expertise in studying primary and secondary pharmacodynamic effects in vital organ systems, for a wide range of test materials, in multiple preclinical species, the company said.